CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
- PMID: 7543139
- PMCID: PMC2192127
- DOI: 10.1084/jem.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
Abstract
The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigen-presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. CTLA-4, a T cell surface glycoprotein that is related to CD28, can also interact with B7-1 and B7-2. However, less is known about the function of CTLA-4, which is expressed at highest levels after activation. We have generated an antibody to CTLA-4 to investigate the consequences of engagement of this molecule in a carefully defined system using highly purified T cells. We show here that the presence of low levels of B7-2 on freshly explanted T cells can partially inhibit T cell proliferation, and this inhibition is mediated by interactions with CTLA-4. Cross-linking of CTLA-4 together with the TCR and CD28 strongly inhibits proliferation and IL-2 secretion by T cells. Finally, results show that CD28 and CTLA-4 deliver opposing signals that appear to be integrated by the T cell in determining the response to activation. These data strongly suggest that the outcome of T cell antigen receptor stimulation is regulated by CD28 costimulatory signals, as well as inhibitory signals derived from CTLA-4.
Comment in
-
Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?J Exp Med. 1995 Aug 1;182(2):289-92. doi: 10.1084/jem.182.2.289. J Exp Med. 1995. PMID: 7543133 Free PMC article. Review. No abstract available.
Similar articles
-
B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.J Immunol. 2001 Aug 1;167(3):1830-8. doi: 10.4049/jimmunol.167.3.1830. J Immunol. 2001. PMID: 11466409
-
Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways.J Immunol. 2002 Sep 15;169(6):2832-6. doi: 10.4049/jimmunol.169.6.2832. J Immunol. 2002. PMID: 12218093
-
The role of B7 costimulation in CD4/CD8 T cell homeostasis.J Immunol. 2000 Apr 1;164(7):3543-53. doi: 10.4049/jimmunol.164.7.3543. J Immunol. 2000. PMID: 10725709
-
Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?J Exp Med. 1995 Aug 1;182(2):289-92. doi: 10.1084/jem.182.2.289. J Exp Med. 1995. PMID: 7543133 Free PMC article. Review. No abstract available.
-
The CD28-B7 costimulatory pathway and its role in autoimmune disease.J Leukoc Biol. 1997 Aug;62(2):156-62. doi: 10.1002/jlb.62.2.156. J Leukoc Biol. 1997. PMID: 9261329 Review.
Cited by
-
Evolving synergistic combinations of targeted immunotherapies to combat cancer.Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973. Nat Rev Cancer. 2015. PMID: 26205340 Review.
-
Harnessing CD8+ T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions.Clin Transl Med. 2024 Jul;14(7):e1731. doi: 10.1002/ctm2.1731. Clin Transl Med. 2024. PMID: 38935536 Free PMC article. Review.
-
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.Am J Clin Dermatol. 2024 May;25(3):407-419. doi: 10.1007/s40257-023-00841-0. Epub 2024 Feb 8. Am J Clin Dermatol. 2024. PMID: 38329690 Review.
-
Melanoma immunotherapy dominates the field.Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Ann Transl Med. 2016. PMID: 27563656 Free PMC article. Review.
-
The Immunology of Hormone Receptor Positive Breast Cancer.Front Immunol. 2021 May 11;12:674192. doi: 10.3389/fimmu.2021.674192. eCollection 2021. Front Immunol. 2021. PMID: 34135901 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials